Takeda had their choice of all the agents with which to partner, and they selected Contrave. They are not fools. So while we are also fans of Arena and their partner Eisai, and hold a small position on $ARNA, we own 3x as much Orexigen as we see $OREX's lower MCap, and fairly high prob of approval, plus Takeda's much bigger and hungrier sales force are all major pluses.
I agree. Another vintage 1960s pharma remix. This does not qualify as a new drug, and is not novel at all. They need to think deeper and more modern. Not old stuff with nasty side effects, rot your kidneys out.